Evidence map›Paper›PMID 42294209›Full record

ArticleACS omega2026

Leishmanicidal Activity of a Hydrazone Derivative Loaded into Nanocarrier Systems.

Juliana B Nunes, Thalles H F de Souza, Amanda S Lima, Clara O C Lopes, Isabelly F Ferraz de Souza, Raíne P Amaral, Gislaine R Pereira, Fábio A Colombo, Eduardo C Figueiredo, Luciana Azevedo and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Juliana B NunesBiomedical Sciences Institute, Pathology and Parasitology Department, Alfenas Federal University (UNIFAL-MG), 37.130-001 Alfenas, Brazil.
Thalles H F de SouzaBiomedical Sciences Institute, Pathology and Parasitology Department, Alfenas Federal University (UNIFAL-MG), 37.130-001 Alfenas, Brazil.
Amanda S LimaNutrition School, Alfenas Federal University (UNIFAL-MG), 37.130-001 Alfenas, Brazil.
Clara O C LopesSchool of Pharmaceutical Sciences Alfenas Federal University (UNIFAL-MG), 37.130-001 Alfenas, Brazil.
Isabelly F Ferraz de SouzaSchool of Pharmaceutical Sciences Alfenas Federal University (UNIFAL-MG), 37.130-001 Alfenas, Brazil.
Raíne P AmaralBiomedical Sciences Institute, Microbiology and Immunology Department, Alfenas Federal University (UNIFAL-MG), 37.130-001 Alfenas, Brazil.
Gislaine R PereiraSchool of Pharmaceutical Sciences Alfenas Federal University (UNIFAL-MG), 37.130-001 Alfenas, Brazil.
Fábio A ColomboSchool of Pharmaceutical Sciences Alfenas Federal University (UNIFAL-MG), 37.130-001 Alfenas, Brazil.
Eduardo C FigueiredoSchool of Pharmaceutical Sciences Alfenas Federal University (UNIFAL-MG), 37.130-001 Alfenas, Brazil.ORCID https://orcid.org/0000-0002-7883-9717
Luciana AzevedoNutrition School, Alfenas Federal University (UNIFAL-MG), 37.130-001 Alfenas, Brazil.
Luiz F Leomil CoelhoBiomedical Sciences Institute, Microbiology and Immunology Department, Alfenas Federal University (UNIFAL-MG), 37.130-001 Alfenas, Brazil.ORCID https://orcid.org/0000-0003-4289-384X
Luis F Cunha Dos ReisBiomedical Sciences Institute, Structural Biology Department, Alfenas Federal University (UNIFAL-MG), 37.130-001 Alfenas, Brazil.ORCID https://orcid.org/0009-0000-1572-2581
Lídia M LimaFaculty of Pharmacy, Federal University of Rio de Janeiro (UFRJ), Av. Carlos Chagas Filho, 373, Cidade Universitária, Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.ORCID https://orcid.org/0000-0002-8625-6351
Marcos J MarquesBiomedical Sciences Institute, Pathology and Parasitology Department, Alfenas Federal University (UNIFAL-MG), 37.130-001 Alfenas, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Visceral leishmaniasis (VL) is a neglected parasitic disease whose treatment is limited by parasite resistance, drug toxicity, and high costs. Seeking safer and more effective therapies, we evaluated the hydrazone derivative LASSBio-1736, a cysteine protease inhibitor hydrazone derivative, which demonstrated plasma stability and low initial hepatic and renal toxicity, focusing on its oral delivery in bovine serum albumin nanoparticles (LASSBio-1736n). An HPLC-UV method was validated for quantitative analysis in biological samples, showing high sensitivity, precision, and linearity. Standardized in vitro digestion (INFOGEST) and Caco-2 assays demonstrated enhanced bioaccessibility and intestinal permeability of the nanoformulation. In the INFOGEST model, LASSBio-1736n maintained structural integrity and drug content, with a 239.7% increase between gastric and intestinal phases compared to the free compound (LASSBio-1736f). Caco-2 assays further confirmed higher apparent permeability, supporting improved oral absorption. In vivo efficacy was evaluated in golden hamsters (

Identifiers

PMID42294209
PMCPMC13261406

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.